Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative review

被引：6

作者：

Hyung, Jaewon ^{[1
]}

Lee, Sang Soo ^{[2
]}

Hwang, Dae Wook ^{[3
]}

Park, Jin-Hong ^{[4
]}

Kim, Kyu-Pyo ^{[1
]}

Yoo, Changhoon ^{[1
]}

机构：

[1] Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, 8 Olymp Ro,43 Gil, Seoul 05505, South Korea

[2] Univ Ulsan, Asan Med Ctr, Dept Gastroenterol, Coll Med, Seoul, South Korea

[3] Univ Ulsan, Asan Med Ctr, Dept Surg, Coll Med, Seoul, South Korea

[4] Univ Ulsan, Asan Med Ctr, Dept Radiat Oncol, Coll Med, Seoul, South Korea

来源：

CHINESE CLINICAL ONCOLOGY | 2022年 / 11卷 / 03期

关键词：

Locally advanced pancreatic cancer (LAPC); neoadjuvant therapy; preoperative therapy; conversion surgery; pancreatic ductal adenocarcinoma (PDAC); STEREOTACTIC BODY RADIOTHERAPY; PACLITAXEL PLUS GEMCITABINE; NAB-PACLITAXEL; PREOPERATIVE TREATMENT; DUCTAL ADENOCARCINOMA; CANCER; FOLFIRINOX; CHEMOTHERAPY; MULTICENTER; SURGERY;

D O I：

10.21037/cco-21-166

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background and Objective: The concept of neoadjuvant approach for patients with locally advanced pancreatic cancer (LAPC) has been evolving with the advancement in therapeutic modalities. In this narrative review, we aimed to discuss the updates and future perspectives on the treatment of LAPC. Methods: We discussed the recent literature and up-to-date evidence along with the future perspectives for the treatment of LAPC using the neoadjuvant approach. Reviewed literatures were searched by systematic search of PubMed and Google Scholar, including articles published in English between January 1st, 2013, and October 31st, 2021. Key Content and Findings: We aimed to review the efficacy outcomes of modern-era chemotherapy regimens and chemoradiation therapy for LAPC based on the results of up-to-date clinical trials and pivotal observational studies. Moreover, we aimed to discuss the role of conversion surgery and studies on the prediction of resectability after neoadjuvant therapy along with the necessity of adjuvant therapy for patients who have received neoadjuvant systemic treatments. Finally, we have addressed several unanswered questions regarding the optimal management of patients with LAPC and determined the future directions by introducing some ongoing trials. Conclusions: Current chemotherapy and chemoradiation therapy has improved clinical outcomes and the conversion surgery rate in patients with LAPC. Future randomized clinical trials and biomarker studies are needed to provide better evidence that can aid in the selection of optimal treatment modalities for individual patients.

引用

页数：14

共 80 条

[1] The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study [J].

Akita, Hirofumi ;

Takahashi, Hidenori ;

Asukai, Kei ;

Tomokuni, Akira ;

Wada, Hiroshi ;

Marukawa, Satoko ;

Yamasaki, Tomoyuki ;

Yanagimoto, Yoshitomo ;

Takahashi, Yusuke ;

Sugimura, Keijiro ;

Yamamoto, Kazuyoshi ;

Nishimura, Junichi ;

Yasui, Masayoshi ;

Omori, Takeshi ;

Miyata, Hiroshi ;

Ochi, Ayami ;

Kagawa, Ayano ;

Soh, Yuko ;

Taniguchi, Yuko ;

Ohue, Masayuki ;

Yano, Masahiko ;

Sakon, Masato .

CLINICAL NUTRITION ESPEN, 2019, 33 :148-153

[2] Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association [J].

Al-Hawary, Mahmoud M. ;

Francis, Isaac R. ;

Chari, Suresh T. ;

Fishman, Elliot K. ;

Hough, David M. ;

Lu, David S. ;

Macari, Michael ;

Megibow, Alec J. ;

Miller, Frank H. ;

Mortele, Koenraad J. ;

Merchant, Nipun B. ;

Minter, Rebecca M. ;

Tamm, Eric P. ;

Sahani, Dushyant V. ;

Simeone, Diane M. .

GASTROENTEROLOGY, 2014, 146 (01) :291-+

[3] Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer A Multicenter Observational Study (NAPOLEON Study) [J].

Arima, Shiho ;

Kawahira, Machiko ;

Shimokawa, Mototsugu ;

Ido, Akio ;

Koga, Futa ;

Ueda, Yujiro ;

Nakazawa, Junichi ;

Komori, Azusa ;

Otsu, Satoshi ;

Fukahori, Masaru ;

Makiyama, Akitaka ;

Taguchi, Hiroki ;

Honda, Takuya ;

Shibuki, Taro ;

Mitsugi, Kenji ;

Nio, Kenta ;

Ide, Yasushi ;

Ureshino, Norio ;

Mizuta, Toshihiko ;

Shirakawa, Tsuyoshi ;

Otsuka, Taiga .

PANCREAS, 2021, 50 (07) :957-964

[4] Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis [J].

Barenboim, Alex ;

Lahat, Guy ;

Geva, Ravit ;

Nachmany, Ido ;

Nakache, Richard ;

Goykhman, Yaacov ;

Brazowski, Eli ;

Rosen, Galia ;

Isakov, Ofer ;

Wolf, Ido ;

Klausner, Joseph M. ;

Lubezky, Nir .

EJSO, 2018, 44 (10) :1619-1623

[5] Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer [J].

Boone, Brian A. ;

Steve, Jennifer ;

Krasinskas, Alyssa M. ;

Zureikat, Amer H. ;

Lembersky, Barry C. ;

Gibson, Michael K. ;

Stoller, Ronald G. ;

Zeh, Herbert J. ;

Bahary, Nathan .

JOURNAL OF SURGICAL ONCOLOGY, 2013, 108 (04) :236-241

[6] Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only Multicenter Propensity Score-matched Analysis [J].

Brada, Lilly J. H. ;

Daamen, Lois A. ;

Magermans, Lisa G. ;

Walma, Marieke S. ;

Latifi, Diba ;

van Dam, Ronald M. ;

de Hingh, Ignace H. ;

Liem, Mike S. L. ;

de Meijer, Vincent E. ;

Patijn, Gijs A. ;

Festen, Sebastiaan ;

Stommel, Martijn W. J. ;

Bosscha, Koop ;

Polee, Marco B. ;

Nio, Yung C. ;

Wessels, Frank J. ;

de Vries, Jan J. J. ;

van Lienden, Krijn P. ;

Bruijnen, Rutger C. ;

Busch, Olivier R. ;

Koerkamp, Bas Groot ;

van Eijck, Casper ;

Molenaar, Quintus, I ;

Wilmink, Hanneke J. W. ;

van Santvoort, Hjalmar C. ;

Besselink, Marc G. .

ANNALS OF SURGERY, 2021, 274 (05) :729-735

[7] Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms [J].

Brada, Lilly J. H. ;

Walma, Marieke S. ;

Daamen, Lois A. ;

van Roessel, Stijn ;

van Dam, Ronald M. ;

de Hingh, Ignace H. ;

Liem, Mike L. S. ;

de Meijer, Vincent E. ;

Patijn, Gijs A. ;

Festen, Sebastiaan ;

Stommel, Martijn W. J. ;

Bosscha, Koop ;

Polee, Marco B. ;

Nio, C. Yung ;

Wessels, Frank J. ;

de Vries, Jan J. J. ;

van Lienden, Krijn P. ;

Bruijnen, Rutger C. ;

Los, Maartje ;

Mohammad, Nadia Haj ;

Wilmink, Hanneke W. ;

Busch, Olivier R. ;

Besselink, Marc G. ;

Molenaar, I. Quintus ;

van Santvoort, Hjalmar C. .

JOURNAL OF SURGICAL ONCOLOGY, 2021, 124 (04) :589-597

[8] Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine [J].

Casolino, R. ;

Braconi, C. ;

Malleo, G. ;

Paiella, S. ;

Bassi, C. ;

Milella, M. ;

Dreyer, S. B. ;

Froeling, F. E. M. ;

Chang, D. K. ;

Biankin, A., V ;

Golan, T. .

ANNALS OF ONCOLOGY, 2021, 32 (02) :183-196

[9] Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX [J].

Choi, Young Hoon ;

Lee, Sang Hyub ;

You, Min Su ;

Shin, Bang Sup ;

Paik, Woo Hyun ;

Ryu, Ji Kon ;

Kim, Yong-Tae ;

Kwon, Wooil ;

Jang, Jin-Young ;

Kim, Sun-Whe .

GUT AND LIVER, 2021, 15 (02) :315-323

[10] Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer -: A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer Study [J].

Conroy, T ;

Paillot, B ;

François, E ;

Bugat, R ;

Jacob, JH ;

Stein, U ;

Nasca, S ;

Metges, JP ;

Rixe, O ;

Michel, P ;

Magherini, E ;

Hua, A ;

Deplanque, G .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1228-1236

← 1 2 3 4 5 6 7 8 →